Molecular Medicine; Molecular Biology; Genetics; Pharmacology; Drug Discovery
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Olivet, Julien ; Université de Liège - ULiège > Département GxABT > Microbial, food and biobased technologies
Maseko, Sibusiso Bonginkhost ; Université de Liège - ULiège > Département GxABT > Microbial, food and biobased technologies ; Université de Liège - ULiège > GIGA > GIGA Molecular Biology of Diseases - Gene Expression & Cancer
Volkov, Alexander N; VIB-VUB Center for Structural Biology, Flemish Institute of Biotechnology (VIB), Brussels, Belgium, Jean Jeener NMR Centre, Free University of Brussels (VUB), Brussels, Belgium
Salehi-Ashtiani, Kourosh; Division of Science and Math, New York University Abu Dhabi, Abu Dhabi, UAE
Das, Kalyan; Structural Biology Unit, Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research and Department of Microbiology, Immunology and Transplantation, Catholic University of Leuven (KU Leuven), Leuven, Belgium
Calderwood, Michael A; Center for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute (DFCI), Boston, MA, USA, Department of Genetics, Blavatnik Institute, Harvard Medical School (HMS), Boston, MA, USA, Department of Cancer Biology, Dana-Farber Cancer Institute (DFCI), Boston, MA, USA
Twizere, Jean-Claude ✱; Université de Liège - ULiège > Département GxABT > Microbial, food and biobased technologies
Gorgulla, Christoph ✱; Department of Cancer Biology, Dana-Farber Cancer Institute (DFCI), Boston, MA, USA, Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School (HMS), Boston, MA, USA, Department of Physics, Faculty of Arts and Sciences, Harvard University, Cambridge, MA, USA. Electronic address: cgorgulla@g.harvard.edu
✱ These authors have contributed equally to this work.
Language :
English
Title :
A systematic approach to identify host targets and rapidly deliver broad-spectrum antivirals.
Publication date :
28 February 2022
Journal title :
Molecular Therapy
ISSN :
1525-0016
eISSN :
1525-0024
Publisher :
Cell Press, United States
Peer reviewed :
Peer Reviewed verified by ORBi
Funding text :
J.O. thanks Wallonie-Bruxelles International (WBI-World Excellence Fellowship), the Belgian F.R.S.-FNRS-T?l?vie (FC27371, Cr?dit no. 7454518F), and the Rega Institute for Medical Research, KU Leuven for the financial support. This work was in part supported by NIAID R21 AI153738 awarded to M.A.C. and by the NYU Abu Dhabi Faculty Research Fund AD060 awarded to K.S.-A. J.-C.T. is a Ma?tre de Recherche of the Belgian F.R.S.-FNRS. C.G. thanks ChemAxon for a free academic license. This work was in part supported by NIH grants CA200913, AI037581, and GM129026 awarded to Gerhard Wagner, as well as by the ARO grant W911NF1910302 to Arthur Jaffe. J.O. J.-C.T. and C.G. wrote the manuscript with critical insight from S.B.M. A.N.V. K.S.-A. K.D. and M.A.C. All authors discussed the proposed methodology and experimental approaches. C.G. is the cofounder of two companies, Virtual Discovery, Inc. and Quantum Therapeutics, Inc. which are engaged in drug discovery activities, in part using VirtualFlow.J.O. thanks Wallonie-Bruxelles International (WBI-World Excellence Fellowship), the Belgian F.R.S.-FNRS-Télévie (FC27371, Crédit no. 7454518F ), and the Rega Institute for Medical Research, KU Leuven for the financial support. This work was in part supported by NIAID R21 AI153738 awarded to M.A.C. and by the NYU Abu Dhabi Faculty Research Fund AD060 awarded to K.S.-A. J.-C.T. is a Maître de Recherche of the Belgian F.R.S.-FNRS. C.G. thanks ChemAxon for a free academic license. This work was in part supported by NIH grants CA200913 , AI037581 , and GM129026 awarded to Gerhard Wagner, as well as by the ARO grant W911NF1910302 to Arthur Jaffe.
Flint, S.J., Racaniello, V.R., Rall, G.F., Hatziioannou, T., Skalka, A.M., Principles of virology. Pathogenesis and Control, Vol. 2, 2020, John Wiley & Sons.
Christ, F., Shaw, S., Demeulemeester, J., Desimmie, B.A., Marchand, A., Butler, S., Smets, W., Chaltin, P., Westby, M., Debyser, Z., et al. Small-molecule inhibitors of the LEDGF/p75 binding site of integrase block HIV replication and modulate integrase multimerization. Antimicrob. Agents Chemother. 56 (2012), 4365–4374.
Lu, H., Zhou, Q., He, J., Jiang, Z., Peng, C., Tong, R., Shi, J., Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials. Signal Transduct Target Ther, 5, 2020, 213.
Clackson, T., Wells, J.A., A hot spot of binding energy in a hormone-receptor interface. Science 267 (1995), 383–386.
Trepte, P., Kruse, S., Kostova, S., Hoffmann, S., Buntru, A., Tempelmeier, A., Secker, C., Diez, L., Schulz, A., Klockmeier, K., et al. LuTHy: a double-readout bioluminescence-based two-hybrid technology for quantitative mapping of protein–protein interactions in mammalian cells. Mol. Syst. Biol., 14, 2018, e8071.
Choi, S.G., Olivet, J., Cassonnet, P., Vidalain, P.O., Luck, K., Lambourne, L., Spirohn, K., Lemmens, I., Dos Santos, M., Demeret, C., et al. Maximizing binary interactome mapping with a minimal number of assays. Nat. Commun., 10, 2019, 3907.
Trepte, P., Secker, C., Choi, S.G., Olivet, J., Ramos, E.S., Cassonnet, P., Golusik, S., Zenkner, M., Beetz, S., Sperling, M., et al. A quantitative mapping approach to identify direct interactions within complexomes. Preprint at bioRxiv, 2021, 10.1101/2021.08.25.457734.
Milhas, S., Raux, B., Betzi, S., Derviaux, C., Roche, P., Restouin, A., Basse, M.J., Rebuffet, E., Lugari, A., Badol, M., et al. Protein-protein interaction inhibition (2P2I)-oriented chemical library accelerates hit discovery. ACS Chem. Biol. 11 (2016), 2140–2148.
Torchet, R., Druart, K., Ruano, L.C., Moine-Franel, A., Borges, H., Doppelt-Azeroual, O., Brancotte, B., Mareuil, F., Nilges, M., Ménager, H., et al. The iPPI-DB initiative: a community-centered database of protein-protein interaction modulators. Bioinformatics 37 (2021), 89–96.
Dougherty, P.G., Qian, Z., Pei, D., Macrocycles as protein-protein interaction inhibitors. Biochem. J. 474 (2017), 1109–1125.
Dorr, P., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M., Mori, J., Rickett, G., Smith-Burchnell, C., Napier, C., et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49 (2005), 4721–4732.
Tan, Q., Zhu, Y., Li, J., Chen, Z., Han, G.W., Kufareva, I., Li, T., Ma, L., Fenalti, G., Li, J., et al. Structure of the CCR5 chemokine receptor–HIV entry inhibitor maraviroc complex. Science 341 (2013), 1387–1390.
Luck, K., Kim, D.K., Lambourne, L., Spirohn, K., Begg, B.E., Bian, W., Brignall, R., Cafarelli, T., Campos-Laborie, F.J., Charloteaux, B., et al. A reference map of the human binary protein interactome. Nature 580 (2020), 402–408.
The ORFeome Collaboration. The ORFeome collaboration: a genome-scale human ORF-clone resource. Nat. Methods 13 (2016), 191–192.
Huttlin, E.L., Bruckner, R.J., Navarrete-Perea, J., Cannon, J.R., Baltier, K., Gebreab, F., Gygi, M.P., Thornock, A., Zarraga, G., Tam, S., et al. Dual proteome-scale networks reveal cell-specific remodeling of the human interactome. Cell 184 (2021), 3022–e28.
Gordon, D.E., Jang, G.M., Bouhaddou, M., Xu, J., Obernier, K., White, K.M., O'Meara, M.J., Rezelj, V.V., Guo, J.Z., Swaney, D.L., et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 583 (2020), 459–468.
Kim, D.-K., Weller, B., Lin, C.-W., Sheykhkarimli, D., Knapp, J.J., Kishore, N., Sauer, M., Rayhan, A., Young, V., Marin-de la Rosa, N., et al. A map of binary SARS-CoV-2 protein interactions implicates host immune regulation and ubiquitination. Preprint at bioRxiv, 2021, 10.1101/2021.03.15.433877.
Maseko, S., Van Molle, I., Blibek, K., Gorgulla, C., Olivet, J., Blavier, J., Vandermeulen, C., Skupiewski, S., Saha, D., Ntombela, T., et al. Interactome and structural basis for targeting the human T-cell leukemia virus Tax oncoprotein. Preprint at bioRxiv, 2021, 10.1101/2021.08.25.457680.
Tunyasuvunakool, K., Adler, J., Wu, Z., Green, T., Zielinski, M., Žídek, A., Bridgland, A., Cowie, A., Meyer, C., Laydon, A., et al. Highly accurate protein structure prediction for the human proteome. Nature 596 (2021), 590–596.
Kim, H.H., Hyun, J.S., Choi, J., Choi, K.E., Jee, J.G., Park, S.J., Structural ensemble-based docking simulation and biophysical studies discovered new inhibitors of Hsp90 N-terminal domain. Sci. Rep., 8, 2018, 368.
Hori, K., Ajioka, K., Goda, N., Shindo, A., Takagishi, M., Tenno, T., Hiroaki, H., Discovery of potent disheveled/dvl inhibitors using virtual screening optimized with NMR-based docking performance index. Front. Pharmacol., 9, 2018, 983.
Hughes, T.E.T., Del Rosario, J.S., Kapoor, A., Yazici, A.T., Yudin, Y., Fluck, E.C. III, Filizola, M., Rohacs, T., Moiseenkova-Bell, V.Y., Structure-based characterization of novel TRPV5 inhibitors. eLife, 8, 2019, e49572.
Cole, B.A., Johnson, R.M., Dejakaisaya, H., Pilati, N., Fishwick, C.W.G., Muench, S.P., Lippiat, J.D., Structure-based identification and characterization of inhibitors of the epilepsy-associated KNa1.1 (KCNT1) potassium channel. iScience, 23, 2020, 101100.
Gorgulla, C., Boeszoermenyi, A., Wang, Z.-F., Fischer, P.D., Coote, P.W., Das, K.M.P., Malets, Y.S., Radchenko, D.S., Moroz, Y.S., Scott, D.A., et al. An open-source drug discovery platform enables ultra-large virtual screens. Nature 580 (2020), 663–668.
Yizhak, K., Gabay, O., Cohen, H., Ruppin, E., Model-based identification of drug targets that revert disrupted metabolism and its application to ageing. Nat. Commun., 4, 2013, 2632.
Venayak, N., von Kamp, A., Klamt, S., Mahadevan, R., MoVE identifies metabolic valves to switch between phenotypic states. Nat. Commun., 9, 2018, 5332.
Brunk, E., Sahoo, S., Zielinski, D.C., Altunkaya, A., Dräger, A., Mih, N., Gatto, F., Nilsson, A., Preciat Gonzalez, G.A., Aurich, M.K., et al. Recon3D enables a three-dimensional view of gene variation in human metabolism. Nat. Biotechnol. 36 (2018), 272–281.
